Why the study?
Does pegylated liposomal doxorubicin improve outcomes compared to continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia?
Does pegylated liposomal doxorubicin improve outcomes compared to continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia?
In elderly patients with acute lymphoblastic leukemia, pegylated liposomal doxorubicin did not improve outcomes compared to continuous-infusion doxorubicin, although it was associated with reduced toxicities.
With the drug schedules used in this study, pegylated liposomal doxorubicin did not improve the outcome of elderly patients with acute lymphoblastic leukemia despite reduced toxicities.
No takes yet. Share an insight, caveat, or question.
Hunault et al. (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: